Predicting axillary response to neoadjuvant chemotherapy using peritumoral and intratumoral ultrasound radiomics in breast cancer subtypes
To explore machine learning (ML)-based breast tumor peritumoral (P) and intratumoral ultrasound radiomics signatures (IURS) for predicting axillary response to neoadjuvant chemotherapy (NAC) in patients with breast cancer (BC) with node-positive. A total of 435 patients were divided into hormone rec...
Gespeichert in:
Veröffentlicht in: | iScience 2024-09, Vol.27 (9), p.110716, Article 110716 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | To explore machine learning (ML)-based breast tumor peritumoral (P) and intratumoral ultrasound radiomics signatures (IURS) for predicting axillary response to neoadjuvant chemotherapy (NAC) in patients with breast cancer (BC) with node-positive. A total of 435 patients were divided into hormone receptor (HR)+/human epidermal growth factor receptor (HER)2-, HER2+, and triple-negative (TN) subtypes. ML classifiers including random forest (RF), support vector machine (SVM), and linear discriminant analysis (LDA) were applied to construct PURS, IURS, and the combined P-IURS radiomics models. SVM of the TN subtype obtained the most favorable performance with an AUC of 0.917 (95%CI: 0.859, 0.960) in PURS models, RF of the HER2+ subtype yielded the highest efficacy in IURS models [AUC = 0.935 (95%CI: 0.843, 0.976)]. The RF-based combined P-IURS model of the HER2+ subtype improved the efficacy to a maximum AUC of 0.952 (95%CI: 0.868, 0.994). ML-based US radiomics can be a promising biomarker to predict axillary response.
[Display omitted]
•Axillary response to NAC is an important indicator for predicting prognosis•This study constructed PURS, IURS, and the combined P-IURS predictive models•The RF-based combined P-IURS model in the HER2+ subtype achieved the highest performance•ML-based US radiomics can be a promising biomarker to help clinical strategies
Bioinformatics; Cancer |
---|---|
ISSN: | 2589-0042 2589-0042 |
DOI: | 10.1016/j.isci.2024.110716 |